Company Overview

Amylyx Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company focused on developing and commercializing therapies for neurodegenerative, endocrine, and rare diseases. The company operates within the biotechnology and pharmaceutical industries, with a strategy centered on targeting disease mechanisms associated with cellular dysfunction, neuroinflammation, and metabolic stress. Amylyx became widely known through the development of AMX0035, marketed as RELYVRIO in the United States for amyotrophic lateral sclerosis (ALS) before its withdrawal from the market in 2024 following Phase 3 trial results that did not confirm clinical benefit. The company continues to advance a pipeline of investigational therapies across neurological and metabolic disorders.

Amylyx’s primary business activities include drug research and development, clinical trials, regulatory engagement, and commercialization efforts for approved or investigational therapies. Key pipeline assets have included avexitide for post-bariatric hypoglycemia and congenital hyperinsulinism, as well as investigational programs targeting Wolfram syndrome and progressive supranuclear palsy. The company’s positioning has historically emphasized rapid development pathways for serious diseases with limited treatment options, supported by collaborations with academic researchers, patient advocacy groups, and specialized clinical centers. Amylyx was founded in 2013 by Joshua Cohen and Justin Klee and completed its initial public offering on Nasdaq in 2022 under the ticker AMLX.

Business Operations

Amylyx generates revenue primarily through product sales, licensing arrangements, and collaboration-related activities tied to its therapeutic portfolio. Historically, the company’s principal commercial asset was RELYVRIO, though the company discontinued marketing and sales activities related to the therapy after announcing negative confirmatory trial outcomes. Following that transition, Amylyx has focused operational resources on advancing clinical-stage programs within its broader pipeline. Its operations include preclinical research, outsourced manufacturing oversight, clinical development management, regulatory affairs, and commercialization planning.

The company conducts operations primarily in the United States but also maintains international clinical and regulatory activities in regions including Europe and Canada. Amylyx relies extensively on third-party contract research organizations, manufacturing partners, and academic collaborators rather than maintaining large-scale in-house manufacturing infrastructure. Strategic assets include intellectual property associated with neuroprotective and metabolic therapies, orphan-drug development expertise, and relationships with rare disease research institutions. Amylyx has also expanded through licensing and acquisition activity, including the acquisition of Avexitide-related assets through its purchase of Eiger BioPharmaceuticals’ endocrinology program assets during bankruptcy proceedings.

Strategic Position & Investments

Amylyx’s strategic direction has shifted toward diversification beyond ALS and toward rare endocrine and neurodegenerative diseases with significant unmet medical need. The company has prioritized advancing late-stage and mid-stage clinical assets, particularly avexitide for hypoglycemia-related disorders and AMX0114 for ALS-associated calpain-2 inhibition research. Management has emphasized maintaining financial flexibility while reallocating capital toward programs viewed as having clearer regulatory and commercial pathways after the discontinuation of RELYVRIO.

The company has pursued growth through targeted acquisitions, licensing arrangements, and internal pipeline development rather than large-scale mergers. Amylyx has invested in rare disease infrastructure and clinical development capabilities, particularly in disorders with orphan-drug opportunities. Emerging areas of focus include neurodegeneration, metabolic dysfunction, and protein-misfolding-related diseases. Public disclosures, including SEC filings and investor presentations, indicate that the company intends to continue leveraging external scientific collaborations and selective asset acquisitions to expand its development portfolio.

Geographic Footprint

Amylyx is headquartered in Cambridge, Massachusetts, and maintains operational activities concentrated in North America, while also supporting clinical and regulatory initiatives internationally. The company has conducted clinical trials and regulatory interactions across multiple jurisdictions, including the United States, Canada, and several European countries. Prior commercialization activities for RELYVRIO and related partnerships expanded the company’s visibility across major pharmaceutical markets.

Although Amylyx remains substantially U.S.-focused in terms of workforce and infrastructure, its therapeutic programs target global rare disease populations. International engagement has included regulatory submissions, expanded-access initiatives, and collaborations with clinical research networks outside the United States. The company’s geographic influence is primarily tied to its clinical development footprint rather than extensive international manufacturing or distribution infrastructure.

Leadership & Governance

Amylyx was co-founded by Joshua Cohen and Justin Klee, who developed the company while students at Brown University. Leadership has consistently emphasized patient-focused drug development, accelerated pathways for severe diseases, and collaboration with scientific and patient communities. Corporate governance is overseen by a board of directors with experience in biotechnology, pharmaceuticals, finance, and healthcare operations.

Key executives include:

• Joshua Cohen – Co-Chief Executive Officer and Co-Founder
• Justin Klee – Co-Chief Executive Officer and Co-Founder
• Michael D. Moss – President and General Counsel
• Stacy Lindborg, Ph.D. – Senior Vice President, Clinical Development
• Sandra J. Horning, M.D. – Director
• Mark Fishman, M.D. – Director

Company leadership has publicly stated that its strategic vision centers on advancing therapies for serious and underserved diseases through scientifically differentiated approaches and disciplined capital allocation. Publicly available governance disclosures in SEC filings and annual reports indicate a continued focus on clinical execution, regulatory engagement, and long-term portfolio development.